J
Jorge E. Romaguera
Researcher at University of Texas MD Anderson Cancer Center
Publications - 300
Citations - 15214
Jorge E. Romaguera is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Mantle cell lymphoma & Rituximab. The author has an hindex of 59, co-authored 300 publications receiving 14081 citations. Previous affiliations of Jorge E. Romaguera include University of Texas at Austin & Hackensack University Medical Center.
Papers
More filters
Journal ArticleDOI
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
Michael L. Wang,Simon Rule,Peter Martin,Andre Goy,Rebecca Auer,Brad S. Kahl,Brad S. Kahl,Wojciech Jurczak,Ranjana H. Advani,Jorge E. Romaguera,Michael E. Williams,Jacqueline C. Barrientos,Ewa Chmielowska,John Radford,Stephan Stilgenbauer,Martin Dreyling,Wiesław Wiktor Jędrzejczak,Peter Johnson,Stephen E. Spurgeon,Lei Li,Liang Zhang,Kate J. Newberry,Zhishuo Ou,Nancy Cheng,Bingliang Fang,Jesse McGreivy,Fong Clow,Joseph J. Buggy,Betty Y. Chang,Darrin M. Beaupre,Lori Kunkel,Kristie A. Blum +31 more
TL;DR: Ibrutinib shows durable single-agent efficacy in relapsed or refractory mantle-cell lymphoma and is enrolled into two groups: patients who had previously received at least 2 cycles of bortezomib therapy and those who had received less than 2 complete cycles.
Journal ArticleDOI
Phase III Study to Evaluate Temsirolimus Compared With Investigator's Choice Therapy for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
Georg Hess,Raoul Herbrecht,Jorge E. Romaguera,Gregor Verhoef,Michael Crump,Christian Gisselbrecht,Anna Laurell,Fritz Offner,Andrew Strahs,Anna Berkenblit,Orysia Hanushevsky,Jill S. Clancy,Becker Hewes,Laurence Moore,Bertrand Coiffier +14 more
TL;DR: Temsirolimus 175 mg weekly for 3 weeks followed by 75 mg weekly significantly improved PFS and objective response rate compared with investigator's choice therapy in patients with relapsed or refractory MCL.
Journal ArticleDOI
High Rate of Durable Remissions After Treatment of Newly Diagnosed Aggressive Mantle-Cell Lymphoma With Rituximab Plus Hyper-CVAD Alternating With Rituximab Plus High-Dose Methotrexate and Cytarabine
Jorge E. Romaguera,Luis Fayad,Maria A Rodriguez,Kristine Broglio,Frederick B. Hagemeister,Barbara Pro,Peter McLaughlin,Anas Younes,Felipe Samaniego,Andre Goy,Andreas H. Sarris,Nam H. Dang,Michael Wang,Virginia Beasley,L. Jeffrey Medeiros,Ruth L. Katz,Harish Gagneja,Barry I. Samuels,Terry L. Smith,Fernando Cabanillas +19 more
TL;DR: Rituximab plus hyper-CVAD alternating with rituxIMab plus high-dose methotrexate and cytarabine is effective in untreated aggressive MCL and toxicity is significant but expected.
Journal ArticleDOI
Phase II Study of Proteasome Inhibitor Bortezomib in Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma
Andre Goy,Anas Younes,Peter McLaughlin,Barbara Pro,Jorge E. Romaguera,Frederick B. Hagemeister,Luis Fayad,Nam H. Dang,F. Samaniego,Michael Wang,Kristine Broglio,Barry I. Samuels,Frederic Gilles,Andreas H. Sarris,Susan Hart,Elizabeth Trehu,David P. Schenkein,Fernando Cabanillas,Alma Rodriguez +18 more
TL;DR: Bortezomib showed promising activity in relapsed mantle-cell lymphoma and encouraging results in other B-cells lymphomas and in combination with other cytotoxic or biologic agents.
Journal ArticleDOI
Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial
Jason R. Westin,Fuliang Chu,Min Zhang,Luis Fayad,Larry W. Kwak,Nathan Fowler,Jorge E. Romaguera,Fredrick B. Hagemeister,Michelle A. Fanale,Felipe Samaniego,Lei Feng,Veerabhadran Baladandayuthapani,Zhiqiang Wang,Wencai Ma,Yanli Gao,Michael J. Wallace,Luis M Vence,Laszlo Radvanyi,Tariq Muzzafar,Rinat Rotem-Yehudar,R. Eric Davis,Sattva S. Neelapu +21 more
TL;DR: The combination of pidilizumab and rituximab was well tolerated, with no autoimmune or treatment-related adverse events of grade 3 or 4, and the results suggest that immune checkpoint blockade is worthy of further study in follicular lymphoma.